Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma

Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma

Objective: Gemcitabine plus nab-paclitaxel (GnP) is the standard first-line therapy for advanced pancreatic ductal adenocarcinoma (PDAC). S-1, an oral fluoropyrimidine derivative, as compared with gemcitabine, is non-inferior in terms of overall survival (OS) and is associated with lower hematologic...

Bibliografske podrobnosti
Main Authors:	Zhou Zhu, Hui Tang, Jinrong Ying, Yuejuan Cheng, Xiang Wang, Yingyi Wang, Chunmei Bai
Format:	Article
Jezik:	English
Izdano:	China Anti-Cancer Association 2023-10-01
Serija:	Cancer Biology & Medicine
Teme:	advanced pancreatic cancer first-line chemotherapy gemcitabine s-1 nab-paclitaxel
Online dostop:	https://www.cancerbiomed.org/content/20/10/765

Podobne knjige/članki

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
od: Jane E. Rogers, et al.
Izdano: (2020-08-01)

Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use
od: Elena Ferris Villanueva, et al.
Izdano: (2015-02-01)

Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
od: Zong Y, et al.
Izdano: (2020-12-01)

Low‐dose gemcitabine plus nab‐paclitaxel versus standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial
od: Ken Kamata, et al.
Izdano: (2023-09-01)

Study of Gemcitabine Plus Nab-Paclitaxel-Based Chemotherapy Regimen as First-Line Treatment in Metastatic Pancreatic Carcinoma
od: Kshitij Domadia, et al.
Izdano: (2022-01-01)

Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab‐paclitaxel as first‐line chemotherapy for advanced pancreatic adenocarcinoma: A single‐center retrospective analysis
od: Konstantin Schlick, et al.
Izdano: (2023-08-01)

Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer
od: Min Su You, et al.
Izdano: (2018-11-01)

Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study
od: Ruihua Xu, et al.
Izdano: (2017-12-01)

Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting
od: Braiteh F, et al.
Izdano: (2017-04-01)

Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
od: Ursula M. Vogl, et al.
Izdano: (2019-01-01)

Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer
od: Chiorean EG, et al.
Izdano: (2018-05-01)

Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer
od: Annalisa Comandatore, et al.
Izdano: (2022-01-01)

Factors affecting the efficacy of gemcitabine and nab-paclitaxel (paclitaxel + albumin) combination in the Russian patient population: results of a multicenter retrospective study
od: I. A. Pokataev, et al.
Izdano: (2019-12-01)

Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma
od: Emerson Y. Chen, et al.
Izdano: (2023-06-01)

Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic Cancer
od: Zhan Shi, et al.
Izdano: (2022-03-01)

Phase II clinical trial of nab‐paclitaxel plus cisplatin plus gemcitabine (NABPLAGEM) in patients with untreated advanced pancreatic cancer
od: Gayle S. Jameson, et al.
Izdano: (2024-06-01)

Economic evaluation of NALIRIFOX vs. nab-paclitaxel and gemcitabine regimens for first-line treatment of metastatic pancreatic ductal adenocarcinoma from U.S. perspective
od: Hanqiao Shao, et al.
Izdano: (2024-09-01)

A Near-Complete Response to Treatment with Gemcitabine plus nab®-Paclitaxel in a Patient with Metastatic Pancreatic Cancer and Poor Performance Status: A Case Report
od: Abdur R. Shakir
Izdano: (2014-10-01)

Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study
od: Suayib Yalcin, et al.
Izdano: (2020-03-01)

Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab‐paclitaxel plus gemcitabine as second or later‐line treatment
od: Guido Giordano, et al.
Izdano: (2024-06-01)

Combination L-Glutamine with Gemcitabine and Nab-Paclitaxel in Treatment-Naïve Advanced Pancreatic Cancer: The Phase I GlutaPanc Study Protocol
od: Jun Gong, et al.
Izdano: (2023-05-01)

Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
od: Masashi Sawada, et al.
Izdano: (2020-05-01)

A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer
od: Kellie L. Bodeker, et al.
Izdano: (2024-11-01)

Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution
od: Qi Quan, et al.
Izdano: (2020-12-01)

Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer
od: Jiayuan Chen, et al.
Izdano: (2021-07-01)

Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel
od: Hakon Blomstrand, et al.
Izdano: (2020-10-01)

Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer
od: Volker Kunzmann, et al.
Izdano: (2014-09-01)

Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial
od: Yannan Zhao, et al.
Izdano: (2018-10-01)

Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study
od: Ana Fernández, et al.
Izdano: (2018-11-01)

Successful conversion surgery for locally advanced gallbladder cancer after gemcitabine and nab-paclitaxel chemotherapy
od: Ziyi Yang, et al.
Izdano: (2022-08-01)

18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer
od: Ronald L. Korn, et al.
Izdano: (2017-08-01)

PD-1 blockade combined with gemcitabine plus nab-paclitaxel is superior to chemotherapy alone in the management of unresectable stage III/IV pancreatic cancer: a retrospective real-world study
od: Daoan Cheng, et al.
Izdano: (2023-10-01)

Efficacy and safety of neoadjuvant nab‐paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single‐arm phase II study (NAC‐GA trial)
od: Ken‐ichi Okada, et al.
Izdano: (2023-11-01)

Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015)
od: Daisaku Yamada, et al.
Izdano: (2021-08-01)

Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study
od: Chen Chang, et al.
Izdano: (2021-05-01)

Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-nab-paclitaxel in advanced pancreatic cancer
od: Lenka N.C. Boyd, et al.
Izdano: (2024-09-01)

Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocol
od: Alfredo Budillon, et al.
Izdano: (2024-09-01)

Molecular analysis of XPO1 inhibitor and gemcitabine–nab‐paclitaxel combination in KPC pancreatic cancer mouse model
od: Md. Hafiz Uddin, et al.
Izdano: (2023-12-01)

Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection
od: Adam R. Wolfe, et al.
Izdano: (2020-07-01)

Phase II study of nab-paclitaxel with gemcitabine for relapsed/refractory small cell lung cancer
od: Margaret M. Byrne, et al.
Izdano: (2024-07-01)